All In Biotech

Drug Trial Radar · NCT03850873

A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics

A Phase I Clinical, Tolerance and Pharmacokinetic Evaluation of 1 Schedules of Oral TQB3616,A Cyclin-Dependent Kinase Inhibitor ,In Patients With Advanced Breast Cancer

Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

May 20, 2019

Primary completion

Sep 23, 2021

Study completion Sep 23, 2021

Sponsor

Sponsor type
Industry
First posted
Feb 22, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TQB3616 may work in cancer by stopping cancer cells from multiplying.TQB3616 is in a new class of drugs called CDK inhibitors.This research study is the first time that TQB3616 will be given to people.TQB3616 is taken by mouth daily.

Conditions

  • Advanced Breast Cancer

Interventions

  • TQB3616Drug

    TQB3616 administerde days 28 of a 28-day schedule,doses ranging from 20m,40mg,60mg,80mg,100mg,120mg once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTTime frame: Baseline up to 28 days
  2. MTDTime frame: Baseline up to 28 days

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Fifth Medical Center of Chinese People's Liberation Army General Hospital

    Beijing, Beijing Municipality, China

  • The Fourth Hospital of Hebei Medical University and Hebei

    Shijiazhuang, Hebei, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.